DK2335074T3 - Individuel optimering af 5-fluoruracildosis ved folfox-behandling - Google Patents

Individuel optimering af 5-fluoruracildosis ved folfox-behandling

Info

Publication number
DK2335074T3
DK2335074T3 DK08875930.3T DK08875930T DK2335074T3 DK 2335074 T3 DK2335074 T3 DK 2335074T3 DK 08875930 T DK08875930 T DK 08875930T DK 2335074 T3 DK2335074 T3 DK 2335074T3
Authority
DK
Denmark
Prior art keywords
fluoruracil
dosage
individual optimization
folfox treatment
folfox
Prior art date
Application number
DK08875930.3T
Other languages
English (en)
Inventor
Erick Gamelin
Michele Boisdron-Celle
Alain Morel
Original Assignee
Inst Cancerologie De L Ouest I C O
Univ Angers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Cancerologie De L Ouest I C O, Univ Angers filed Critical Inst Cancerologie De L Ouest I C O
Application granted granted Critical
Publication of DK2335074T3 publication Critical patent/DK2335074T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK08875930.3T 2008-09-26 2008-09-26 Individuel optimering af 5-fluoruracildosis ved folfox-behandling DK2335074T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/055625 WO2010035075A1 (en) 2008-09-26 2008-09-26 Individual 5-fluorouracile dose optimization in folfox treatment

Publications (1)

Publication Number Publication Date
DK2335074T3 true DK2335074T3 (da) 2013-06-17

Family

ID=40626871

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08875930.3T DK2335074T3 (da) 2008-09-26 2008-09-26 Individuel optimering af 5-fluoruracildosis ved folfox-behandling

Country Status (9)

Country Link
US (1) US20110246079A1 (da)
EP (1) EP2335074B1 (da)
JP (1) JP2012503639A (da)
AU (1) AU2008362108B2 (da)
CA (1) CA2738753C (da)
DK (1) DK2335074T3 (da)
ES (1) ES2414505T3 (da)
RU (1) RU2482496C2 (da)
WO (1) WO2010035075A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010035076A1 (en) * 2008-09-26 2010-04-01 Centre Regional De Lutte Contre Le Cancer D'angers Individual 5-fluorouracile dose optimization in folfiri treatment
EP3446704A1 (en) 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
AU2018220861B2 (en) 2017-02-14 2021-08-19 Isofol Medical Ab Methods for increasing blood plasma 2'-deoxyuridine (dUrd) and thymidylate synthase inhibition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097086A2 (en) * 2004-04-02 2005-10-20 Adventrx Pharmaceuticals, Inc. Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
FR2884257B1 (fr) * 2005-04-12 2010-11-26 Centre Regional De Lutte Contre Le Cancer Dangers Prevention des toxicites dues au 5-fluorouracile
RU2297630C1 (ru) * 2005-10-04 2007-04-20 Общество с ограниченной ответственностью "Витальные системы+" Способ определения концентрации лекарственного препарата в биологических средах человека при лечении онкологических больных

Also Published As

Publication number Publication date
ES2414505T3 (es) 2013-07-19
AU2008362108B2 (en) 2015-09-03
CA2738753C (en) 2018-11-06
WO2010035075A1 (en) 2010-04-01
CA2738753A1 (en) 2010-04-01
AU2008362108A1 (en) 2010-04-01
RU2011112494A (ru) 2012-11-10
EP2335074B1 (en) 2013-03-20
EP2335074A1 (en) 2011-06-22
US20110246079A1 (en) 2011-10-06
JP2012503639A (ja) 2012-02-09
RU2482496C2 (ru) 2013-05-20

Similar Documents

Publication Publication Date Title
DK2222272T3 (da) Behandling af luftvejssygdom
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2500017T3 (da) Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse
DK2709453T3 (da) Anvendelse af thiazolid-forbindelser til forebyggelse og behandling af virussygdomme, cancer og sygdomme forårsaget af intracellulære infektioner
DK2205257T3 (da) Doseringsforskrifter for LAG-3Ig (IMP321) til anvendelse ved behandling af cancer
BRPI0917883A2 (pt) Métodos e compostos para o tratamento e prevenção da doença citrus greening
BRPI0812293A2 (pt) Derivados de 2-oxo-3-benzilbenzoxazol-2 -ona e compostos relacionados como inibidores de met quinase para o tratamento de tumores
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK3276004T3 (da) Fremgangsmåder til behandling af kronisk nyresygdom
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
DK2627345T3 (da) Formuleringer til behandling af sygdomme i de øvre luftveje
DK2872497T4 (da) Chromanyl-derivater til behandling af mitokondriel sygdom
DK2506712T3 (da) Morfinanderivater til behandling af lægemiddeloverdosering
DK3045474T3 (da) Terapeutiske midler til behanlding af sygdomme, der er forbundet med uønsket celleproliferation
DK2346509T3 (da) Inhalation af levofloxacin til at reducere lungeinflammation
BR112012020585A2 (pt) composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase
DK2252317T3 (da) Behandling af makuladegeneration
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0915439A2 (pt) composição tópica para o tratamento de ceratose actínica
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0909270A2 (pt) Compostos de sirna para inibição de rtp801
HK1161837A1 (en) Use of nifuratel to treat infections caused by atopobium species
BR112013017164A2 (pt) composto, composição farmacêutica, método de inibir pask, método de tratamento de uma doença, método para obter um efeito em um paciente e método de tratamento de uma doença mediada por pask
DK2501381T3 (da) Behandling af atrieflimmer
DK2254570T3 (da) Kombination omfattende paclitaxel til behandling af ovariecancer